{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T11:18:10Z","timestamp":1777807090660,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["BR 3723\/3-1"],"award-info":[{"award-number":["BR 3723\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00213-017-4747-x","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T02:18:50Z","timestamp":1506997130000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats"],"prefix":"10.1007","volume":"235","author":[{"given":"Emilia","family":"Tarland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz H.","family":"Pertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Brosda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"4747_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neubiorev.2016.02.008","volume":"64","author":"S Aznar","year":"2016","unstructured":"Aznar S, Hervig MS (2016) The 5-HT2A serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases. Neurosci Biobehav Rev 64:63\u201382","journal-title":"Neurosci Biobehav Rev"},{"key":"4747_CR2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0022-3565(25)23831-9","volume":"271","author":"VP Bakshi","year":"1994","unstructured":"Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787\u2013794","journal-title":"J Pharmacol Exp Ther"},{"key":"4747_CR3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.neuropharm.2005.05.013","volume":"49","author":"LA Bruins Slot","year":"2005","unstructured":"Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005) Effects of novel antipsychotics with mixed D2 antagonist\/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49:996\u20131006","journal-title":"Neuropharmacology"},{"key":"4747_CR4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","volume":"29","author":"A Bartolomeis de","year":"2015","unstructured":"de Bartolomeis A, Tomasetti C, Iasevoli F (2015) Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 29:773\u2013799","journal-title":"CNS Drugs"},{"key":"4747_CR5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/0269881114565806","volume":"29","author":"J Dunlop","year":"2015","unstructured":"Dunlop J, Brandon NJ (2015) Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? J Psychopharmacol 29:230\u2013238","journal-title":"J Psychopharmacol"},{"key":"4747_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bbr.2009.12.036","volume":"215","author":"A Ennaceur","year":"2010","unstructured":"Ennaceur A (2010) One-trial object recognition in rats and mice: methodological and theoretical issues. Behav Brain Res 215:244\u2013254","journal-title":"Behav Brain Res"},{"key":"4747_CR7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","volume":"31","author":"A Ennaceur","year":"1988","unstructured":"Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31:47\u201359","journal-title":"Behav Brain Res"},{"key":"4747_CR8","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1007\/s00213-016-4356-0","volume":"233","author":"RT Franke","year":"2016","unstructured":"Franke RT, Tarland E, Fink H, Pertz HH, Brosda J (2016) 2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats. Psychopharmacology 233:3041\u20133050","journal-title":"Psychopharmacology"},{"key":"4747_CR9","doi-asserted-by":"crossref","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523\u20131631","DOI":"10.1152\/physrev.2000.80.4.1523"},{"key":"4747_CR10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","volume":"156","author":"MA Geyer","year":"2001","unstructured":"Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117\u2013154","journal-title":"Psychopharmacology"},{"issue":"Suppl 2","key":"4747_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-2007-979350","volume":"31","author":"MA Geyer","year":"1998","unstructured":"Geyer MA (1998) Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31(Suppl 2):73\u201379","journal-title":"Pharmacopsychiatry"},{"key":"4747_CR12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbr.2014.10.025","volume":"285","author":"B Grayson","year":"2015","unstructured":"Grayson B, Leger M, Piercy C, Adamson L, Harte M, Neill JC (2015) Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav Brain Res 285:176\u2013193","journal-title":"Behav Brain Res"},{"key":"4747_CR13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","volume":"184","author":"B Grayson","year":"2007","unstructured":"Grayson B, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31\u201338","journal-title":"Behav Brain Res"},{"key":"4747_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","volume":"72","author":"MF Green","year":"2004","unstructured":"Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41\u201351","journal-title":"Schizophr Res"},{"key":"4747_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2009.08.002","volume":"115","author":"Y Guo","year":"2009","unstructured":"Guo Y, Zhang H, Chen X, Cai W, Cheng J, Yang Y, Jin G, Zhen X (2009) Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand. Schizophr Res 115:41\u201349","journal-title":"Schizophr Res"},{"key":"4747_CR16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/FBP.0b013e32833fa7df","volume":"21","author":"A Gururajan","year":"2010","unstructured":"Gururajan A, Taylor DA, Malone DT (2010) Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav Pharmacol 21:690\u2013709","journal-title":"Behav Pharmacol"},{"key":"4747_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-244X-8-95","volume":"8","author":"L Hanssens","year":"2008","unstructured":"Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W (2008) The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 8:95","journal-title":"BMC Psychiatry"},{"key":"4747_CR18","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/npp.2012.64","volume":"37","author":"M Horiguchi","year":"2012","unstructured":"Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT1A partial agonist. Neuropsychopharmacology 37:2175\u20132183","journal-title":"Neuropsychopharmacology"},{"key":"4747_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1124\/jpet.113.205997","volume":"347","author":"F Jantschak","year":"2013","unstructured":"Jantschak F, Brosda J, Franke RT, Fink H, M\u00f6ller D, H\u00fcbner H, Gmeiner P, Pertz HH (2013) Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and \u03b12C-adrenergic receptors, and its antipsychotic-like effects in rats. J Pharmacol Exp Ther 347:57\u201368","journal-title":"J Pharmacol Exp Ther"},{"key":"4747_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201\u2013225","journal-title":"Neuropsychopharmacology"},{"key":"4747_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0893-133X(98)00004-9","volume":"19","author":"JD Jentsch","year":"1998","unstructured":"Jentsch JD, Taylor JR, Roth RH (1998) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19:105\u2013113","journal-title":"Neuropsychopharmacology"},{"key":"4747_CR22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0006-3223(91)90025-H","volume":"30","author":"VA Keith","year":"1991","unstructured":"Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30:557\u2013566","journal-title":"Biol Psychiatry"},{"key":"4747_CR23","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"SF Kim","year":"2007","unstructured":"Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104:3456\u20133459","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4747_CR24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"4747_CR25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0006-3223(02)01344-6","volume":"52","author":"L Leumann","year":"2002","unstructured":"Leumann L, Feldon J, Vollenweider FX, Ludewig K (2002) Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry 52:729\u2013739","journal-title":"Biol Psychiatry"},{"key":"4747_CR26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00213-011-2536-5","volume":"220","author":"L Lyon","year":"2012","unstructured":"Lyon L, Saksida LM, Bussey TJ (2012) Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology 220:647\u2013672","journal-title":"Psychopharmacology"},{"key":"4747_CR27","doi-asserted-by":"crossref","unstructured":"L\u00f6schmann PA, Horowski R, Wachtel H (1992) Bromerguride\u2014an ergoline derivative with atypical neuroleptic properties. Clin Neuropharmacol 15(Suppl 1):263A\u2013264A","DOI":"10.1097\/00002826-199201001-00137"},{"key":"4747_CR28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00212846","volume":"94","author":"RS Mansbach","year":"1988","unstructured":"Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94:507\u2013514","journal-title":"Psychopharmacology"},{"key":"4747_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S1461145705005328","volume":"8","author":"MM Marcus","year":"2005","unstructured":"Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH (2005) Combined \u03b12 and D2\/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315\u2013327","journal-title":"Int J Neuropsychopharmacol"},{"key":"4747_CR30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393\u2013406","journal-title":"Annu Rev Med"},{"key":"4747_CR31","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1017\/S1461145713000928","volume":"16","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M (2013) Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 16:2181\u20132194","journal-title":"Int J Neuropsychopharmacol"},{"key":"4747_CR32","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.neubiorev.2013.09.012","volume":"37","author":"MJ Millan","year":"2013","unstructured":"Millan MJ, Bales KL (2013) Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci Biobehav Rev 37:2166\u20132180","journal-title":"Neurosci Biobehav Rev"},{"key":"4747_CR33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","volume":"202","author":"T Nagai","year":"2009","unstructured":"Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 202:315\u2013328","journal-title":"Psychopharmacology"},{"key":"4747_CR34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2013.09.011","volume":"24","author":"JC Neill","year":"2014","unstructured":"Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM (2014) Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur Neuropsychopharmacol 24:822\u2013835","journal-title":"Eur Neuropsychopharmacol"},{"key":"4747_CR35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419\u2013432","journal-title":"Pharmacol Ther"},{"key":"4747_CR36","doi-asserted-by":"crossref","unstructured":"Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY (2015) Combined serotonin 5-HT1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behav Brain Res 285:165\u2013175","DOI":"10.1016\/j.bbr.2014.09.040"},{"key":"4747_CR37","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 28:421\u2013453","journal-title":"CNS Drugs"},{"key":"4747_CR38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0707005","volume":"150","author":"J Sallinen","year":"2007","unstructured":"Sallinen J, H\u00f6glund I, Engstr\u00f6m M, Lehtim\u00e4ki J, Virtanen R, Sirvi\u00f6 J, Wurster S, Savola JM, Haapalinna A (2007) Pharmacological characterization and CNS effects of a novel highly selective \u03b12C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150:391\u2013402","journal-title":"Br J Pharmacol"},{"key":"4747_CR39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bcpt.12090","volume":"113","author":"J Sallinen","year":"2013","unstructured":"Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtim\u00e4ki J, Piepponen P, Mijatovic J, Tanila H, Virtanen R, Sirvi\u00f6 J, Haapalinna A (2013) Pharmacological characterisation of a structurally novel \u03b12C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113:239\u2013249","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4747_CR40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00213-010-2091-5","volume":"214","author":"S Snigdha","year":"2011","unstructured":"Snigdha S, Idris N, Grayson B, Shahid M, Neill JC (2011) Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology 214:843\u2013853","journal-title":"Psychopharmacology"},{"key":"4747_CR41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbr.2007.10.012","volume":"187","author":"S Snigdha","year":"2008","unstructured":"Snigdha S, Neill JC (2008a) Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats\u2014a preliminary investigation. Behav Brain Res 187:489\u2013494","journal-title":"Behav Brain Res"},{"key":"4747_CR42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2008.03.018","volume":"191","author":"S Snigdha","year":"2008","unstructured":"Snigdha S, Neill JC (2008b) Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 191:26\u201331","journal-title":"Behav Brain Res"},{"key":"4747_CR43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00213-008-1072-4","volume":"199","author":"NR Swerdlow","year":"2008","unstructured":"Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199:331\u2013388","journal-title":"Psychopharmacology"},{"key":"4747_CR44","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0022-3565(25)21289-7","volume":"279","author":"NR Swerdlow","year":"1996","unstructured":"Swerdlow NR, Bakshi V, Geyer MA (1996) Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290\u20131299","journal-title":"J Pharmacol Exp Ther"},{"key":"4747_CR45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpsyc.1994.03950020063007","volume":"51","author":"NR Swerdlow","year":"1994","unstructured":"Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139\u2013154","journal-title":"Arch Gen Psychiatry"},{"key":"4747_CR46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A \u00dccok","year":"2008","unstructured":"\u00dccok A, Gaebel W (2008) Side effects of atypical antipsychotics: a brief overview. World Psychiatry 7:58\u201362","journal-title":"World Psychiatry"},{"key":"4747_CR47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pnpbp.2016.07.002","volume":"71","author":"M Uys","year":"2016","unstructured":"Uys M, Shahid M, Sallinen J, Dreyer W, Cockeran M, Harvey BH (2016) The \u03b12C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol. Prog Neuro-Psychopharmacol Biol Psychiatry 71:108\u2013116","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"4747_CR48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.euroneuro.2015.04.014","volume":"25","author":"A Vreeker","year":"2015","unstructured":"Vreeker A, van Bergen AH, Kahn RS (2015) Cognitive enhancing agents in schizophrenia and bipolar disorder. Eur Neuropsychopharmacol 25:969\u20131002","journal-title":"Eur Neuropsychopharmacol"},{"key":"4747_CR49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145706006638","volume":"10","author":"ML Wadenberg","year":"2007","unstructured":"Wadenberg ML, Wiker C, Svensson TH (2007) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive \u03b12 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191\u2013202","journal-title":"Int J Neuropsychopharmacol"},{"key":"4747_CR50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.euroneuro.2013.11.008","volume":"24","author":"CA Wilson","year":"2014","unstructured":"Wilson CA, Koenig JI (2014) Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 24:759\u2013773","journal-title":"Eur Neuropsychopharmacol"},{"key":"4747_CR51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0269881114555252","volume":"29","author":"JW Young","year":"2015","unstructured":"Young JW, Geyer MA (2015) Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol 29:178\u2013196","journal-title":"J Psychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4747-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4747-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4747-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:52:47Z","timestamp":1750895567000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4747-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4747"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4747-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,3]]}}}